Danish firm Zymenex Holding, which develops biologic drugs for rare and life-threatening genetic disorders, will be purchased by Chiesi Group. Chiesi said the deal would allow it to establish a position in the rare-disease drug market. The acquisition will give Chiesi access to a late-stage drug candidate for alpha-Mannosidosis and several early-stage compounds.

Related Summaries